medicare coverage of glp-1 Nearly Four Million Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare Bridge GLP-1 Weight-Loss Drug Demonstration Begins
Description
Jama , 2024, 331.1: 38-48
Semaglutide is approved as a treatment for type 2 diabetes under the brand name Ozempic, semaglutide has gained significant recognition for its effectiveness in promoting substantial weight loss
Why the new trial matters The TAG-MS trial, reported by Multiple Sclerosis News Today on May 7, is structured to address the mechanism question directly
Among weight loss products, its Orlistat, the active ingredient in alli, is a lipase inhibitor and works by binding to specific enzymes that break down fats
